Studies have showed using TriageHF reduced all-cause hospitalisations by 58% according to Ahmed et al. (2024). Using ...

This page provides a summary of the findings from the report. It includes insight from Dr John Graham, consultant oncologist and cancer lead clinician at Taunton and Somerset NHS Foundation Trust, ...

How has our guidance been used in practice? NICE impact reports review how our guidance is used to improve the health and care of people. We base the reports on data from national audits, reports, ...

All NICE products on uterine prolapse. Includes any guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We need to prioritise areas of guidance development and delivery that will have the greatest impact on the health and care system. To do this we're developing a new centralised approach.

These resources provide access to high quality authoritative evidence and best practice. They are for anyone who works in health and social care and makes decisions about treatments, interventions, or ...

Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the test to be evaluated. If it ...